MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.urolonc.2020.04.025

Медицинская библиотека · Urologic oncology · 2020

Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.

Singla Nirmish, Christie Alana, Freifeld Yuval, Ghandour Rashed A, Woldu Solomon L, Clinton Timothy N, Petros Firas G, Robyak Haley, Yeh Hsin-Chih, Fang Dong, Enikeev Dmitry, Bagrodia Aditya, Sagalowsky Arthur I, Lotan Yair, Raman Jay D, Matin Surena F, Margulis Vitaly

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Whether pathologic stage at radical nephroureterectomy (RNU) can serve as an appropriate surrogate for oncologic outcomes in patients with high-grade (HG) upper tract urothelial carcinoma (UTUC) treated with neoadjuvant chemotherapy (NAC) is not defined. We sought to determine whether patients who achieve pathologically non-muscle-invasive (ypT0, ypTa, ypT1, ypTis) HG UTUC after receipt of NAC exhibit oncologic outcomes comparable to those who are inherently low stage without chemotherapy.

METHODS

We identified 647 UTUC patients who underwent RNU among 3 institutions from 1993to2016. Patients with low or unknown grade, pathologic muscle invasion, or receipt of adjuvant chemotherapy were excluded. We compared clinicopathologic data and oncologic outcomes between pT0-1 and ypT0-1 patients. Kaplan-Meier analysis was used to assess overall (OS), cancer-specific (CSS), and systemic recurrence-free (RFS) survival. Predictors of these endpoints were identified using Cox regression.

RESULTS

234 (43 ypT0-1, 191 pT0-1) patients with HG UTUC were included. Two patients exhibited pathologic complete response after NAC. OS (P = 0.055), CSS (P = 0.152), and RFS (P = 0.098) were similar between ypT0-1 and pT0-1 patients. Predictors of worse outcomes included African-American race (RFS, CSS, and OS), Charlson score (OS), and systemic recurrence (OS and CSS).

CONCLUSIONS

Patients with HG UTUC who achieve ypT0-1 stage after NAC exhibit favorable oncologic outcomes comparable to those inherently non-muscle-invasive who do not receive chemotherapy. Improvements in clinical staging will play an important role in better defining candidacy for NAC in treating HG UTUC while minimizing overtreatment. Furthermore, pathologic stage may serve as an appropriate early surrogate for oncologic endpoints in designing clinical trials.

Для цитирования: Singla Nirmish, Christie Alana, Freifeld Yuval, Ghandour Rashed A, Woldu Solomon L, Clinton Timothy N, Petros Firas G, Robyak Haley, Yeh Hsin-Chih, Fang Dong, Enikeev Dmitry, Bagrodia Aditya, Sagalowsky Arthur I, Lotan Yair, Raman Jay D, Matin Surena F, Margulis Vitaly. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.. Urologic oncology. 2020. DOI: 10.1016/j.urolonc.2020.04.025.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.